Pre-op and post-op osocimab non-inferior to enoxaparin for reducing the incidence of VTE after TKA
This report has been verified
by one or more authors of the
original publication.
JAMA. 2020 Jan 14;323(2):130-139.
Eight hundred and thirteen patients scheduled for a total knee arthroplasty were randomized to receive a single post-operative dose of osocimab (0.3, 0.6, 1.2, 1.8mg/kg) or a pre-operative dose of osocimab (0.3, 1.8mg/kg) for the reduction of thromboembolic events, compared to enoxaparin or apixaban. The primary time-point was at the time of venography (approximately 10-13 days post-operation). Results revealed post-operative doses of osocimab 0.6mg/kg or higher to be non-inferior to enoxaparin for the primary outcome of composite venous thromboembolism at 10-13 days post-operation. The pre-operative 1.8mg/kg dose of osocimab was found to be superior to enoxaparin for the primary outcome.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
